Acumen Pharmaceuticals (ABOS) Common Equity (2020 - 2026)

Acumen Pharmaceuticals has disclosed Common Equity across 7 years of filings, most recently posting $57.3 million for Q2 2026.

• In Q2 2026, Common Equity fell 51.09% year-over-year to $57.3 million; the TTM figure through Jun 2026 stood at $57.3 million (down 51.09% YoY), while the FY2025 annual figure was $70.4 million, down 61.26% from the prior year.
• Common Equity came in at $57.3 million for Q2 2026 at Acumen Pharmaceuticals, down from $87.5 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $280.3 million in Q3 2023 to a low of $57.3 million in Q2 2026.
• Average Common Equity over 5 years is $177.2 million, with a median of $185.3 million recorded in 2022.
• Year-over-year, Common Equity jumped 575.32% in 2022 and sank 61.26% in 2025.
• Over 5 years, Common Equity stood at $188.8 million in 2022, then soared by 41.42% to $267.0 million in 2023, then plunged by 31.9% to $181.8 million in 2024, then slumped by 61.26% to $70.4 million in 2025, then slipped by 18.7% to $57.3 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $57.3 million in Q2 2026, $87.5 million in Q1 2026, and $70.4 million in Q4 2025.